Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461827 | 0.83 | MAPT (0.41) | MAPTGAAALDH1A1NPC1RAB9A | |
| SCHEMBL24113818 | 0.82 | ALDH1A1 (0.35) | MAPTGAAALDH1A1NPC1RAB9A | |
| SCHEMBL20226663 | 0.82 | MAPT (0.40) | MAPTGAAALDH1A1NPC1RAB9A | |
| SCHEMBL19121034 | 0.80 | MAPT (0.39) | MAPTGAAALDH1A1NPC1RAB9A | |
| SCHEMBL23140222 | 0.80 | MAPT (0.41) | MAPTGAAALDH1A1NPC1RAB9A | |
| SCHEMBL21152368 | 0.77 | ALDH1A1 (0.37) | MAPTGAAALDH1A1NPC1RAB9A | |
| SCHEMBL14275617 | 0.75 | MAPT (0.41) | MAPTGAAALDH1A1NPC1RAB9A | |
| SCHEMBL20798481 | 0.74 | MAPT (0.35) | MAPTGAAALDH1A1NPC1RAB9A | |
| SCHEMBL24611277 | 0.73 | — | — | |
| SCHEMBL23073402 | 0.73 | ALDH1A1 (0.43) | ALDH1A1RAB9ASMN1; SMN2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612537-B1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LTD (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-3191490-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2019-08-07 | — | — | EP | disclosed |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | MAPT 2910/4885GAA 2471/4885ALDH1A1 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.